Trial · NCT07138547
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
NCT07138547, Phase 1, Phase 2, Recruiting, Chinese PLA General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma. Trials, record NCT07138547. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07138547
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
- NCT number
- NCT07138547
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Lymphoma
- Interventions
- Eliglustat, CD30 target immunotherapy
- First posted
- 2025-08-24
- Last updated
- 2026-01-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects with treatment-related adverse events (AEs) | Up to 120 days after the last dose of study drugs] | Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. |
| Primary | CR rate (CRR) in the CAR-T cell plus Eliglustat treatment group | 12 months | The Complete Response Rate (CRR), as assessed by the investigator, is the proportion of all evaluable subjects who achieve a complete response. |
| Primary | Progression-free survival (PFS) in the BV plus Eliglustat treatment group. | 2 years | Time from the date of first administration of the study drug to disease progression or death from any cause (any earliest date). |
| Secondary | Objective Response Rate [ORR] | 12 months | The percentage of patients with CR or PR was determined according to the revised lymphoma efficacy evaluation criteria. |
| Secondary | CR rate (CRR) /Progression-free survival (PFS)based on CD30 expression level in tumor tissue. | 12 months | CD30 expression will be evaluated by immunohistochemistry (IHC), and its expression levels will be analyzed for association with CRR/PFS. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07138547
GET https://conductscience.org/api/trials/v1/NCT07138547/registered